Condition: Mycosis Fungoides · Sezary Syndrome · Sponsor: Kyowa Kirin Co., Ltd.
The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.
This description comes directly from the study's public registry record.
HaeMi Park · +82-10-3378-3471 · haemi.park.m8@kyowakirin.com
Always discuss trial participation with your own doctor first.
| Kosin University Gospel Hospital | Busan, Busan Metropolitan City, South Korea | Recruiting |
| Chung-Ang University Hospital | Seoul, South Korea | Terminated |
| Ewha Womans University Mokdong Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07132567